Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) radiopharmaceuticals.
With more than 20 clinical trials underway worldwide (including partnered investigator-led studies), Telix’s core pipeline aims to address significant unmet medical needs in prostate, kidney, brain, and blood cancers as well as a range of hard-to-treat immunologic and rare diseases.
Telix’s lead product for prostate imaging has been approved in Australia, Canada, and the United States.
Meet us at booth 60, 69
Please feel free to contact us if you need more information
Phone: +613 9419 3336